Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 267 entries
View as:

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT05936567 Org: User:
Start: 07/31/23 End: 09/05/25 Due: 09/05/26

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04370704 Org: User:
Start: 07/27/20 End: 08/04/25 Due: 08/04/26

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03762447 Org: User:
Start: 12/10/18 End: 11/17/23 Due: 11/17/24

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT03978637 Org: User:
Start: 02/04/20 End: 10/13/23 Due: 10/13/24

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Phase: N/A Priority: Normal
NCT ID: NCT05722912 Org: User:
Start: - End: - Due: -

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Phase: N/A Priority: Normal
NCT ID: NCT06113445 Org: User:
Start: 11/29/23 End: 05/08/27 Due: 05/08/28

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase: N/A Priority: Normal
NCT ID: NCT03011372 Org: User:
Start: 04/25/17 End: 10/30/24 Due: 10/30/25

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Phase: N/A Priority: Normal
NCT ID: NCT02955940 Org: User:
Start: 11/30/16 End: 09/30/27 Due: 09/30/28

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Phase: N/A Priority: Normal
NCT ID: NCT03322566 Org: User:
Start: 01/09/18 End: 10/16/20 Due: 10/16/21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Phase: N/A Priority: Normal
NCT ID: NCT03424122 Org: User:
Start: 07/02/18 End: 06/27/22 Due: 06/27/23

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Phase: N/A Priority: Normal
NCT ID: NCT00952289 Org: User:
Start: 08/31/09 End: 10/31/15 Due: 10/31/16

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT03569371 Org: User:
Start: 07/17/18 End: 04/22/19 Due: 04/22/20

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT05750823 Org: User:
Start: 04/11/23 End: 03/06/25 Due: 03/06/26

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04849715 Org: User:
Start: 03/11/22 End: 07/07/34 Due: 07/07/35

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01905813 Org: User:
Start: 06/30/13 End: 04/17/26 Due: 04/17/27

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00698789 Org: User:
Start: 05/31/08 End: 06/30/09 Due: 06/30/10

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Phase: N/A Priority: Normal
NCT ID: NCT06958211 Org: User:
Start: 06/12/25 End: 07/11/27 Due: 07/11/28

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05909995 Org: User:
Start: 08/29/23 End: 11/11/24 Due: 11/11/25

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04989387 Org: User:
Start: 10/04/21 End: 09/19/24 Due: 09/19/25

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Phase: N/A Priority: Normal
NCT ID: NCT05127421 Org: User:
Start: 11/10/21 End: 09/29/23 Due: 09/29/24

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03627052 Org: User:
Start: 09/20/18 End: 11/13/19 Due: 11/13/20

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Phase: N/A Priority: Normal
NCT ID: NCT06959225 Org: User:
Start: 06/23/25 End: 07/11/27 Due: 07/11/28

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Phase: N/A Priority: Normal
NCT ID: NCT06516965 Org: User:
Start: 10/10/24 End: 06/02/27 Due: 06/02/28

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06832618 Org: User:
Start: 06/17/25 End: 05/18/28 Due: 05/18/29

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

Phase: N/A Priority: Normal
NCT ID: NCT06843408 Org: User:
Start: 06/25/25 End: 12/31/27 Due: 12/31/28